Conference
A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Abstract
113
Background: The COU-AA-301 trial showed that abiraterone (AA), an oral cytochrome p450 CYP17 inhibitor, improved survival for men with mCRPC progressing after docetaxel. AA is now a standard treatment in this setting. In order to better understand the non-clinical trial experience with AA, we undertook a multicenter retrospective analysis of patients (pts) treated with AA. Methods: Consecutive pts with mCRPC from 5 …
Authors
Clayton R; Heng DYC; Wu JSY; Zielinski R; North SA; Emmenegger U; Hotte SJ; Al-Shamsi HO; Chen L; Eigl BJ
Volume
31
Pagination
pp. 113-113
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2013
DOI
10.1200/jco.2013.31.6_suppl.113
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X